BALTIMORE — Lupin Pharmaceuticals announced on Monday a partnership with Phil, Inc., which will help deliver cost-effective next-generation access solutions for patients who are prescribed Solosec (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.

Solosec is the only single 2g oral dose therapy for the most common vaginal infection in the U.S. among adult women. This treatment is designed to deliver a full course of therapy in just one packet. In November, Lupin announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Solosec (secnidazole) for the treatment of trichomoniasis in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021.

“With the addition of Solosec® to the Phil platform, we are able to provide a convenient channel for physicians to prescribe Solosec® and enhance the patient experience,” said Jon Stelzmiller, president – Specialty, Lupin Pharmaceuticals. “We are proud that Lupin has been at the forefront of advancing affordable healthcare for women globally for decades and we are committed to helping prevent and manage women’s health conditions, including BV.”

“Phil offers a systemic solution for a systemic problem,” Deepak Thomas, founder and CEO of Phil, Inc., said in a statement. “Because the underlying challenges in this space are experienced not just at the pharmacy but may extend to other stakeholders including prescribers and manufacturers, Phil aims to address these issues in their entirety.”